EUVIMEDEUVIMED entdecken
Open Access

Mixing it up: boosting responses with immunotherapy combinations

Hiroki Komatsuda, Edward S Sim, Ravindra Uppaluri

Trends in Cancer · 2025

DOI: 10.1016/j.trecan.2025.04.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Cancer, 2025. Verfasst von Hiroki Komatsuda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical …. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Head and Neck Neoplasms, Immunotherapy. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NIDCD NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Whether combination neoadjuvant immunotherapy can enhance response in patients with head and neck cancer remains unclear. Recently, Li et al. demonstrated improved responses with neoadjuvant anti-PD-1+CTLA-4 or anti-PD-1+LAG-3 compared with anti-PD-1 monotherapy. These combination strategies act via different mechanisms with distinct biomarkers of response, highlighting the potential for personalized neoadjuvant immunotherapy approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsImmunotherapyHumansNeoadjuvant TherapyProgrammed Cell Death 1 ReceptorCTLA-4 AntigenTreatment OutcomeLymphocyte Activation Gene 3 ProteinBiomarkers, Tumor

Stichwörter der Autor:innen

head and neck cancerimmune checkpoint inhibitorneoadjuvant immunotherapysingle-cell RNA sequencing

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCTLA-4 AntigenPDCD1 protein, humanLymphocyte Activation Gene 3 ProteinLag3 protein, humanCTLA4 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Surgery/Otolaryngology, Brigham and Women's Hospital, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Har…

Förderung

  • NIDCR NIH HHS
  • NIDCD NIH HHS
  • National Institutes of Health
  • Merck
  • National Institute on Deafness and Other Communication Disorders

Zitieren

APA

Komatsuda, H., Sim, E. S., & Uppaluri, R. (2025). Mixing it up: boosting responses with immunotherapy combinations. Trends in Cancer. https://doi.org/10.1016/j.trecan.2025.04.013

Vancouver

Komatsuda H, Sim ES, Uppaluri R. Mixing it up: boosting responses with immunotherapy combinations. Trends in Cancer. 2025. doi:10.1016/j.trecan.2025.04.013

BibTeX
@article{Komatsuda2025,
  author = {Komatsuda, Hiroki and Sim, Edward S and Uppaluri, Ravindra},
  title = {Mixing it up: boosting responses with immunotherapy combinations},
  journal = {Trends in Cancer},
  year = {2025},
  doi = {10.1016/j.trecan.2025.04.013}
}
Kostenlos starten →